Trellis Vitality Review: One Complete Table, Four Blanks

Trellis Vitality (trellisvitality.com) sells five clinician-guided injectable programs, and its GLP-1 pricing is the best-formed table we read in a batch of seven telehealth sellers screened together in August 2026. Its other four programs publish no ladder at all. A review that reported only the first half would be describing a different company, so this one reports both.

The table that is actually a table

Semaglutide is $150 a month on a one-month plan, $140 a month on three, and $133 a month on six. Tirzepatide is $199, $189 and $179 across the same three columns.¹ Two labels on that table do most of the work: the one-month column is stated to be month-to-month, and the page states that all dosages are available at the same price.

The second of those is the one worth reading twice if you are treating insulin resistance. Tirzepatide adds a second gut-hormone pathway alongside GLP-1, and produced the largest average reductions in the obesity trials² — but the reason to titrate is metabolic response, not the label, and a program that re-prices you at every step turns a clinical decision into a budget decision. Trellis puts that in writing rather than leaving you to infer it from a missing dose column, which is more than The Edit does at a higher price. Our semaglutide versus tirzepatide guide covers the molecule choice itself.

The four programs with no ladder

NAD+, glutathione, Lipo-MIC with B12 and tesamorelin are each advertised with a single "starting at" figure and nothing behind it: from $129, from $93, from $130 and from $299 a month respectively. We pulled the site's build scripts, the rendered pages and the intake flow's data payload. There is no rung table anywhere.

We are not publishing those four as monthly prices, and neither should anyone else. Given that the GLP-1 table's six-month rung sits about 12% below its one-month rung, it is plausible that $129 and $93 are longest-prepay figures and the true month-to-month rungs are higher — but that is an inference from one table applied to four products, and we record it as unverified rather than dressing it up as a finding. If you are shopping the NAD+ line, ask for the one-month figure by email before you start.

A claim the site makes about itself

Trellis's own blog states, twice, that Trellis publishes its complete pricing on the program page. It does not. The GLP-1 page does; the other four publish one qualified number each.³ That gap is small in dollars and large in what it tells you about how carefully the site's copy is checked, which is the same instinct our checklist for judging a program before you pay is built on.

Several marketing statistics on the site — a star rating, a patient count, an average time saved, an average annual saving — carry no source anywhere. We are not repeating them, and a reader should not weigh them either.

Who prescribes, and who compounds

The medical group is Arora Health & Aesthetics, LLC, with Dr. Sean Arora as medical director; his NPI, 1841729449, resolves to an active Family Medicine record in the national registry.⁴ The dispensing pharmacy is named: VialsRX, a state-licensed compounding pharmacy in Houston, Texas. Naming the compounder is unusual in this cohort and it matters, because the pharmacy is where the questions in our compounded versus brand-name guide actually get answered — what is in the vial, who made it, and under which set of standards.

The same medical group and the same medical director also serve The Edit. Different pharmacy, different prices, different catalog — but the two are not independent clinical opinions, and shortlisting both gives you one organization twice.

The paperwork that is thin

Trellis names no legal entity. Its terms page is roughly three kilobytes of text, which is short enough that the absence is structural rather than an oversight, and it means the "no membership, no consult costs" promise and the free assessment are marketing statements without a contractual document behind them. States served are given as all 50. Cancellation terms are not set out with the specificity The Edit publishes.

The FDA screen

We queried the FDA's live warning-letter index in August 2026 for the brand, for its medical group and for its named pharmacy. Nothing matched in the company column.⁵ The pass carried a positive control — an unrelated telehealth seller with a real 2026 letter — which returned correctly, so the zero reflects a clean record rather than a query that failed silently.

Where it lands

For a reader whose treatment plan involves climbing to an effective dose and staying there, Trellis's GLP-1 table is the clearest of the seven: a real month-to-month rung, one price across dosages, and a published discount for committing longer that is presented as a commitment rather than disguised as the standing rate. The rest of the catalog is priced the way the worst of this market prices everything. Read it against our guide to insulin resistance and GLP-1 medicines and the rubric on our Luna Fit Score methodology page. Trellis is not scored there — it is not in our ranking, we have no commercial relationship with it, and this write-up exists because the table is worth seeing and the four blanks are worth naming.